Core and Group Health

A new report shows that the PBMs' critics have already won most of the other high-profile fights.

The critics say the arbitrators are awarding sky-high payments without even explaining why.

The hospital alleges $1.4 million in withheld post-bankruptcy payments following an earlier $250 million reimbursement lawsuit.

The price drop builds on concerted efforts by Novo Nordisk to improve patient access, particularly to weight-loss drugs Wegovy and Ozempic, according to company officials.

The initial focus is on GLP-1 medications, a category that has seen significant demand but variable insurance coverage.

The plaintiffs say the HHS secretary's assurances that coverage will continue are "open to suspicion."